INOVIO INO-3107 Faces Oct 30 PDUFA, $80M Market Cap

The FDA accepted INOVIO’s (NASDAQ: INO) Biologics License Application for INO-3107, a DNA medicine for recurrent respiratory papillomatosis (RRP), with a PDUFA target action date of October 30, 2026. The agency is not currently planning an advisory committee meeting.

Price update August 2, 2026 (Polygon): INO closed at $0.68 on July 31 (Polygon), up from the $0.66 July 30 close but still down 29.9% from the $0.97 reference price. The continued decline follows the $20 million public offering announced July 31, which diluted existing holders at a discount. The market cap has fallen below $50 million. The October 30 PDUFA for INO-3107 in recurrent respiratory papillomatosis remains the binary catalyst.

Update July 31, 2026: INOVIO announced a $20 million public offering of shares and warrants, closing on July 31. The offering prices shares at a discount, diluting existing holders. The stock fell approximately 21% on the offering news to approximately $0.82 per share (per web search; not yet reflected in Polygon close). The capital raise extends INOVIO’s runway but at significant dilution for a sub-$60 million market cap company. The October 30 PDUFA remains the binary catalyst.

The FDA accepted the BLA under the accelerated approval pathway, a route that allows approval based on surrogate endpoints for serious conditions with unmet need. In the file acceptance letter, however, the FDA flagged a potential review issue: it questioned whether INO-3107 meets the eligibility criteria for accelerated approval. INOVIO says it “continues to strongly believe” the drug fulfills those criteria and is not pursuing a traditional approval pathway.

RRP is a rare HPV-related disease where benign tumors grow in the airway, causing voice changes and breathing difficulty. Patients require repeated surgeries to remove the growths. There are no FDA-approved therapies. The condition affects roughly 3,000 adults and 1,200 children in the US.

INO-3107 is INOVIO’s lead product candidate, with Orphan Drug and Breakthrough Therapy designations. The drug uses INOVIO’s DNA medicine platform, which delivers plasmid DNA into cells to trigger an immune response against HPV-6 and HPV-11, the two viral strains that cause RRP. Unlike mRNA or viral vector approaches, DNA medicines are designed to produce antigen longer and without the cold-chain storage requirements.

The BLA is supported by Phase 1/2 data showing 72% of patients had a 50-to-100% reduction in the number of surgeries in the year after starting treatment, and the mean number of surgeries dropped from 4.1 pre-treatment to 1.7 in year one. The drug was generally well tolerated, with mostly Grade 1 adverse effects like injection site pain and fatigue.

If approved, INO-3107 would be the first DNA medicine approved for a non-infectious disease and the first therapy specifically indicated for RRP. The DNA platform itself is a broader thesis for INOVIO; validating it through an FDA approval would open the door to the company’s pipeline of DNA vaccines and therapeutics.

For INOVIO, the stakes are existential. The company’s stock closed at $0.97 on July 24, giving it a market cap of roughly $80 million. The company’s cash runway extends into the first quarter of 2027. If the FDA approves INO-3107, INOVIO becomes a commercial company with its first product. If the FDA rejects the accelerated approval pathway, the company has no near-term alternative and limited capital to pursue a traditional approval route.

The central risk is the accelerated approval question. The FDA’s file acceptance letter flagged this explicitly. If the agency determines INO-3107 does not qualify for accelerated approval, INOVIO would need to run a randomized trial, which it cannot afford at current cash levels. Investors approaching this PDUFA date should understand that the binary outcome here is not just approve-or-reject. It is whether the FDA accepts the accelerated approval framework at all, which the agency has already signaled is in doubt.

What to watch: the October 30 decision and any FDA communication about the accelerated approval eligibility. A request for additional data before that date would be a negative signal.